Ceftriaxone-induced Hepatotoxicity in Patients with Common Medical Infections in Qatar: A Retrospective Study

Overview

Journal Qatar Med J

Specialty General Medicine

Date 2022 Jul 22

PMID 35864919

Authors

Manish Barman

Bassem Al Hariri

Abdul Rahman Mustafa

Naseem Ambra

Israa Amjed

Ahmad Eid Nazzal Alharafsheh

M N Illahi

S Hamuda

Mohamedali Gaafar

Muhammad Sharif

Affiliations

Soon will be listed here.

Abstract

Introduction: Ceftriaxone, a third-generation cephalosporin, is frequently used for the treatment of various bacterial infections as a broad-spectrum antibiotic for many decades. Although ceftriaxone is a well-tolerated drug in most cases, it can lead to serious liver injury, which can be a real challenge to the treating physician. Given the potentially serious adverse effects that can vary from mild biochemical abnormalities to complete liver failure, we intend to assess the spectrum of liver injury based on biochemical criteria for patients treated with ceftriaxone for common bacterial infections in Qatar.

Objectives: This study aimed to explore the incidence of ceftriaxone-induced liver injury at Hazm Mebaireek General Hospital, Qatar, and to evaluate the relationship of the ceftriaxone dose, if any, with liver dysfunction.

Methods: This retrospective study included hospitalized adult patients treated with ceftriaxone at our hospital from January 2019 to December 2019 and analyzed demographic and clinical data obtained from electronic medical records. This study determined the incidence of liver injury (primary outcome) in patients treated with ceftriaxone (2 g/day) for ≥ 2 consecutive days by reviewing liver function test results until the day of discharge and at the first outpatient follow-up.

Results: The final data analysis included a total of 634 patients admitted and treated with ceftriaxone from January 2019 to December 2019.In the multivariate analysis with propensity score adjustment, ceftriaxone was independently associated with liver injury, especially when combined with other agents utilizing hepatic metabolism.

Conclusions: Ceftriaxone was associated with a significantly higher incidence of liver injury (19.7%) when used along with other medications that are metabolized in the liver, as found in the present study compared with other similar studies (approximately 2.9%-13.9%). Furthermore, the incidence was too high to be ignored in clinical practice.

Citing Articles

What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives.

Alfieri C, Molinari P, Cinque F, Vettoretti S, Cespiati A, Bignamini D Int J Mol Sci. 2024; 25(14).

PMID: 39062970 PMC: 11276657. DOI: 10.3390/ijms25147728.

Ceftriaxone-induced cholestatic hepatitis in a child: A case report and a review of the literature.

Castellazzi M, Agostoni C, Palella J, Civeriati D, Marchisio P, Nebbia G Front Pediatr. 2022; 10:1051887.

PMID: 36545656 PMC: 9760817. DOI: 10.3389/fped.2022.1051887.

References

Kaplowitz N . Drug-induced liver injury. Clin Infect Dis. 2004; 38 Suppl 2:S44-8. DOI: 10.1086/381446. View

Weaver R, Blomme E, Chadwick A, Copple I, Gerets H, Goldring C . Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov. 2019; 19(2):131-148. DOI: 10.1038/s41573-019-0048-x. View

Park B, Kitteringham N, Maggs J, Pirmohamed M, Williams D . The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol. 2005; 45:177-202. DOI: 10.1146/annurev.pharmtox.45.120403.100058. View

Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N . Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008; 47(6):2003-9. DOI: 10.1002/hep.22272. View

Shiffman M, Keith F, Moore E . Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology. 1990; 99(6):1772-8. DOI: 10.1016/0016-5085(90)90486-k. View

de Abajo F, Montero D, Madurga M, Garcia Rodriguez L . Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004; 58(1):71-80. PMC: 1884531. DOI: 10.1111/j.1365-2125.2004.02133.x. View

Antoine D, Williams D, Park B . Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin Drug Metab Toxicol. 2008; 4(11):1415-27. DOI: 10.1517/17425255.4.11.1415. View

El Sherrif Y, Potts J, Howard M, Barnardo A, Cairns S, Knisely A . Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations?. Liver Int. 2013; 33(8):1266-70. DOI: 10.1111/liv.12216. View

Manns M, Obermayer-Straub P . Viral induction of autoimmunity: mechanisms and examples in hepatology. J Viral Hepat. 1997; 4 Suppl 2:42-7. DOI: 10.1111/j.1365-2893.1997.tb00179.x. View

10.

Navarro V, Barnhart H, Bonkovsky H, Davern T, Fontana R, Grant L . Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014; 60(4):1399-408. PMC: 4293199. DOI: 10.1002/hep.27317. View

11.

Wong W, Wu P, Yuen M, Cheng C, Yew W, Wong P . Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 1999; 31(1):201-6. DOI: 10.1002/hep.510310129. View

12.

Daly A, Donaldson P, Bhatnagar P, Shen Y, Peer I, Floratos A . HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009; 41(7):816-9. DOI: 10.1038/ng.379. View

13.

Russo M, Hoofnagle J, Gu J, Fontana R, Barnhart H, Kleiner D . Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014; 60(2):679-86. PMC: 4110177. DOI: 10.1002/hep.27157. View

14.

Lucena M, Andrade R, Kaplowitz N, Garcia-Cortes M, Fernandez M, Romero-Gomez M . Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009; 49(6):2001-9. DOI: 10.1002/hep.22895. View

15.

Hillman L, Gottfried M, Whitsett M, Rakela J, Schilsky M, Lee W . Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury. Am J Gastroenterol. 2016; 111(7):958-65. PMC: 5516923. DOI: 10.1038/ajg.2016.114. View

16.

Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C . Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002; 36(2):451-5. DOI: 10.1053/jhep.2002.34857. View

17.

Chitturi S, Farrell G . Drug-induced cholestasis. Semin Gastrointest Dis. 2001; 12(2):113-24. View

18.

Danan G, Benichou C . Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993; 46(11):1323-30. DOI: 10.1016/0895-4356(93)90101-6. View

19.

Chen M, Borlak J, Tong W . High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2012; 58(1):388-96. DOI: 10.1002/hep.26208. View

20.

Abboud G, Kaplowitz N . Drug-induced liver injury. Drug Saf. 2007; 30(4):277-94. DOI: 10.2165/00002018-200730040-00001. View